Visual acuity evaluation of patients of Behcet disease on adalimumab

Document Type : Original Article

Authors

1 Ophthalmology Department, faculty of medicine, Minia University ,Minia,Egypt.

2 Ophthalmology Department, Faculty of Medicine, Minia University

3 Ophthalmology department, faculty of medicine, minia university

4 Ophthalmology department ,MInia university

Abstract

Abstract

Intruduction

Behcet uveitis (BU) is one of major criteria of Behcet disease (BD) that end in macular structural damage.(Yalçındağ, Temel, Şekkeli, & Kar, 2021) Adalimumab (ADA) , which is an anti-TNF alpha biological drug, has proven higher safety in controlling Behcet uveitis over traditional treatment.(van der Houwen et al., 2023)

Aim of study

Evaluation of visual acuity (VA) in patients of BD on adalimumab.

Patients and methods

The study was a case control study. The study included 60 eyes from 60 BU patients that divided into 2 groups. The study was conducted at Ophthalmology department, Minia University Hospital in Egypt between february 2023 and August 2023.

Results

Patient on ADA therapy is very effective in recovery of Visual acuity in BU. This makes ADA has higher preference for achieving better visual prognosis in patients of BU rather than traditional therapy.

Conclusion

ADA is better as a first line of therapy in patients of BD associated with uveitis.

Keywords

Main Subjects

Minia Journal of Medical Research

Articles in Press, Accepted Manuscript
Available Online from 10 March 2024

Files

Share

How to cite

Statistics